Progress in optimizing the immunization schedule of recombinant human papillomavirus vaccines / 中华微生物学和免疫学杂志
Chinese Journal of Microbiology and Immunology
;
(12): 893-900, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-912130
ABSTRACT
Human papillomavirus (HPV) is closely associated with cervical cancer and other anogenital cancers or diseases, and HPV vaccination is an important measure of primary prevention. Currently, there are four licensed HPV vaccines. Clinical trials and real-world studies have confirmed the efficacy and effectiveness of the routine three-dose immunization schedule. Expanding HPV vaccination coverage can accelerate the process of cervical cancer elimination, so optimizing the immunization schedule, including extending dosing intervals and decreasing vaccination doses, is one of the key considerations for future application of HPV vaccines. This review summarized the progress related to the immunogenicity and efficacy of HPV vaccination with fewer doses and non-standard three-dose schedule.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Microbiology and Immunology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS